- Home
- VTVT vs IFRX Comparison
VTVT vs IFRX Comparison
Compare VTVT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- IFRX
- Stock Information
- Founded
- VTVT 2015
- IFRX 2007
- Country
- VTVT United States
- IFRX Germany
- Employees
- VTVT N/A
- IFRX N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- IFRX Health Care
- Exchange
- VTVT Nasdaq
- IFRX Nasdaq
- Market Cap
- VTVT 56.7M
- IFRX 53.5M
- IPO Year
- VTVT 2015
- IFRX 2017
- Fundamental
- Price
- VTVT $14.64
- IFRX $0.79
- Analyst Decision
- VTVT Strong Buy
- IFRX Strong Buy
- Analyst Count
- VTVT 2
- IFRX 4
- Target Price
- VTVT $35.50
- IFRX $7.75
- AVG Volume (30 Days)
- VTVT 7.9K
- IFRX 282.5K
- Earning Date
- VTVT 08-07-2025
- IFRX 08-07-2025
- Dividend Yield
- VTVT N/A
- IFRX N/A
- EPS Growth
- VTVT N/A
- IFRX N/A
- EPS
- VTVT N/A
- IFRX N/A
- Revenue
- VTVT $17,000.00
- IFRX $140,242.00
- Revenue This Year
- VTVT N/A
- IFRX N/A
- Revenue Next Year
- VTVT N/A
- IFRX $6,309.47
- P/E Ratio
- VTVT N/A
- IFRX N/A
- Revenue Growth
- VTVT N/A
- IFRX 30.90
- 52 Week Low
- VTVT $12.12
- IFRX $0.71
- 52 Week High
- VTVT $26.99
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- VTVT 40.96
- IFRX 37.43
- Support Level
- VTVT $14.53
- IFRX $0.78
- Resistance Level
- VTVT $16.76
- IFRX $0.83
- Average True Range (ATR)
- VTVT 0.62
- IFRX 0.04
- MACD
- VTVT 0.04
- IFRX 0.03
- Stochastic Oscillator
- VTVT 25.11
- IFRX 52.00
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.